SLB vs SYRE · P/E 12, rev $8.97B vs $7.60B cap
Schlumberger NV (SLB) versus Spyre Therapeutics Inc. (SYRE) — a side-by-side from cached financials, not a winner call.
Schlumberger NV (SLB) is a oil & gas equipment & services company listed on US. It is led by Olivier Le Peuch.
Spyre Therapeutics Inc. (SYRE) is a biotechnology company listed on NASDAQ.
Latest reported SLB revenue for 2026-06-30 was $8.97B. Net income was $786.0M. Revenue was up 2.9% from 2026-03-31 to 2026-06-30. SLB currently screens at market cap $48.16B and trailing P/E 12.1.
Latest reported SYRE revenue for 2025-12-31 was $0. Net income was -$155.2M. SYRE currently screens at market cap $7.60B.
SLB currently screens at market cap $48.16B and trailing P/E 12.1. SYRE currently screens at market cap $7.60B.
Not investment advice. Open the SLB and SYRE stock pages for the full models.
Not investment advice.